相关实验视频

Updated: Jan 10, 2026

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

减少PCOS肥胖症的影响:方法和治疗结果

Alexa C Dzienny¹, David B Seifer¹

¹Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA.

Journal of personalized medicine

|November 26, 2025

概括

减肥对于管理女性的肥胖和多囊性卵巢综合征 (PCOS) 至关重要. 饮食,药物和手术等干预措施可以改善生殖健康并降低代谢风险.

科学领域:

生殖内分泌学生殖内分泌学
代谢健康代谢健康
肥胖医学肥胖医学

背景情况:

肥胖是一个日益关注的问题,影响了41%的美国女性,并增加了不良健康事件的风险,包括生殖问题,如月经不规则和子宫内膜癌.
肥胖与多囊性卵巢综合征 (PCOS) 密切相关,其特点是高雄性和无排卵. 患有这两种疾病的女性往往会经历更严重的表型,患有慢性无排卵,代谢障碍和降低生育能力的风险增加.
体重管理对肥胖和PCOS患者至关重要,改善心血管风险因素,月经规律,排卵和怀孕率.

研究的目的:

为了审查和比较各种减肥策略,女性肥胖和PCOS.
为临床医生提供基于证据的信息,以指导PCOS管理的个性化治疗决策.
探索改变生活方式,药物和减肥手术对PCOS症状和相关健康风险的影响.

主要方法:

这篇叙事综述综合了当前关于肥胖和PCOS妇女减肥干预措施的文献.
它比较了改变生活方式 (饮食,运动,行为疗法),药物治疗 (例如GLP-1受体激动剂) 和减肥手术的疗效.
该审查考虑了患者目标,风险耐受性和伴随性疾病等因素在治疗选择中.

主要成果:

生活方式的修改,包括低血糖指数饮食 (基,DASH) 和维生素D补充,是基础的第一线干预措施.
新出现的数据突出显示了较新的减肥药物,如GLP-1受体激动剂在控制PCOS和心血管风险方面的作用.
减肥手术和药物治疗提供了显著的减肥和代谢改善,尽管需要对风险和益处进行个性化评估.

结论:

个性化方法对于治疗肥胖妇女的PCOS至关重要,考虑到个体的生殖愿望和健康状况.
减肥干预措施显著改善了PCOS和肥胖妇女的荷尔蒙平衡,胰岛素敏感性,月经功能和生育能力.
临床医生应仔细评估患者特定的因素,以推最有效和可持续的减肥策略来管理PCOS.

关键词:

在PCOS中,PCOS是PCOS.通过饮食摄入的摄入量肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖个性化医疗是个性化的医疗.药物治疗药物治疗身体活动身体活动

更多相关视频

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...